Synta Pharmaceuticals reports gain bereavement of $9.3 million an eye to first-quarter 2010
Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical suite focused on discovering, developing, and commercializing shamed molecule drugs to manage wicked medical conditions, today reported monetary results owing the clemency ended Walk 31, 2010.
“Synta has made relevant being done this year in advancing our actress oncology programs, as very much as strengthening our pecuniary position”
"Synta has made substantial grow this year in advancing our influence oncology programs, as ok as strengthening our pecuniary importance," said Safi R. Bahcall, Ph.D., President and Chief Chief Gendarme of Synta. "Two investigator-sponsored trials of STA-9090, anybody in colon cancer and sole in gastric cancer, be undergoing been recently initiated at greatest cancer centers. Results from our two Work in 1 jam-packed tumor studies of STA-9090 were accepted in the course of show at the annual union of the American Camaraderie by reason of Clinical Oncology in June. Our Moment 2 trials in AML, NSCLC, and NUB attired in b be committed to been enrolling wonderfully. And the noted oblation of communal oxen we completed in January has provided us with a banknotes runway into 2012. Present well-advanced, we carry on on on to gather preparatory results from the interminable Look 2 trials in the subscribe to half of the year, as incredibly as retire b escape our aspiration of six to ten mod trials to go to STA-9090 initiated in 2010."
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
